HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/30/2025 14:17 PDT] HOOKIPA Pharma Inc. (NASDAQ:HOOK), Up By 100% ($0.77) From $0.77 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/17/2025 07:03 PDT] HOOK Expected to Trade Up After Bullish Patterns Develop
• [03/10/2025 07:52 PDT] HOOK Expected to Trade Up After Bullish Patterns Develop
• [03/03/2025 07:42 PST] HOOK Expected to Trade Up After Bullish Patterns Develop